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What is already known on this topic 
Cancer agencies recommend skin self-examination (SSE).  Teledermoscopy (if done during 
clinic visits) has excellent concordance with face-to-face clinical examination, but sensitivity and 
specificity of SSE plus mobile teledermoscopy done by people at home has not been studied.  
What does this study adds 
Sensitivity of SSE plus teledermoscopy ranges from 41.9% to 81.8%, specificity from 56.3% to 
89.6% depending on the analysis method, and it could complement melanoma screening and/or 
surveillance efforts. 
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Abstract 
Background: Early detection by skin self-examination (SSE) could improve outcomes from 
melanoma. Mobile teledermoscopy may aid this process. 
Objectives: To establish clinical accuracy of SSE plus mobile teledermoscopy compared to 
clinical skin examination (CSE) and test whether providing people with detailed SSE 
instructions improves accuracy.  
Methods: Men and women 50-64 years (n=58) performed SSE plus mobile teledermoscopy in 
their homes between May and November 2013 and were given technical instructions plus 
detailed SSE instructions (intervention) or technical instructions only (control). Within three 
months, they underwent a CSE. Outcome measures included: a) body sites examined, lesions 
photographed, and missed; b) sensitivity of SSE plus mobile teledermoscopy compared to in-
person CSE using either patients or lesions as denominator; and, c) concordance of telediagnosis 
with CSE.  
Results: 49 of 58 randomised participants completed the study, and submitted 309 lesions to the 
teledermatologist (156 intervention; 153 control group).  Intervention group participants were 
more likely to submit lesions from their legs compared to control (p=0.03), no other differences 
between groups in number or site of missed lesions.11 participants (22%) did not photograph 14 
pigmented lesions the dermatologist considered worthwhile photographing or requiring clinical 
monitoring. Sensitivity of SSE plus mobile teledermoscopy was 81.8% (95% confidence interval 
64.5-93.0) using the patient as the denominator and 41.9 (27.6-56.2) using the lesion as 
denominator.  There was substantial agreement between telediagnosis and CSE (Kappa =0.90) 
accounting for differential diagnoses.  
Conclusions: SSE plus mobile teledermoscopy is promising for surveillance of particular lesions 
even without provision of detailed SSE instructions, but in the format tested in this study, 
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consumers may overlook lesions and send many non-pigmented lesions. This investigation 
demonstrates that high quality dermoscopic images can be taken by patients at home and for 
those sent telediagnosis is highly accurate. 
Keywords: skin cancer, self-examination, melanoma, teledermatology, cellular phone 
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Introduction 
Melanoma continues to be a major public health concern. The International Agency for Research 
in Cancer reported age-standardised incidence rates of 3.0 per 100 000, ranging widely from 
about 35 per 100 000 in Australia and New Zealand to 0.2 per 100 000 in South-East Asia.1,2  
The incidence continues to rise in fair-skinned populations.3-5 Localised, thin melanomas have a 
better prognosis over thicker lesions;6 therefore, early detection is important in improving 
survival. It is estimated that up to 72% of all melanomas are first detected by non-physicians 
such as the patients themselves or family and friends.7  Lesions found during systematic 
examinations are generally thinner than melanomas found otherwise. Thus, systematic skin self-
examination (SSE) could improve outcomes from melanoma.8,9  One population-based, case-
control study suggested that performing deliberate SSEs may reduce melanoma mortality by 
63%.10  
The widespread use of smartphones (which due to their internet connectivity and built in camera 
are becoming medical diagnostic devices), has opened new pathways which could play a role in 
early detection, or surveillance and monitoring for health concerns.11-14 Specific to skin cancer 
early detection, dermoscopes have been developed which can be attached to smartphones 
(forming a mobile teledermoscope).  This device allows magnified images of skin lesions to be 
taken under polarised light for electronic transmission to a specialist. This store and forward 
process is called mobile teledermoscopy. 15,16 
The inter-rater concordance of clinical diagnoses for lesions assessed during face to face 
consultations versus teledermatology ranges from 68-100% depending on the type of study and 
teledermatology method15,16 In a pilot study enrolling 22 consumers (randomised to SSE only or 
SSE plus mobile teledermoscopy), it appeared feasible that consumers themselves in their home 
environment were able to select and submit skin lesions allowing telediagnosis via mobile 
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teledermoscopy. 17 On average, participants overlooked two suspicious skin lesions the doctor 
considered would have been worthwhile photographing for further monitoring. However 
numbers were small and the study lacked anatomical images to determine the exact location of 
each lesion.  
 
The primary aim of the present study was to describe the sites and types of lesions self-identified 
by patients as being suspicious during SSE, whether participants missed lesions during SSE and 
to see whether this individual selection process differed according to presence or absence of 
detailed SSE instructions. We also sought to estimate the sensitivity, specificity and concordance 
of mobile teledermoscopy when compared against CSE. 
 
Materials and Methods 
Ethics approval was granted by the ethics committees of the QIMR Berghofer Medical Research 
Institute and the Queensland University of Technology (#1200000553) and the trial was 
registered with the Australian and New Zealand Clinical Trials Registry number 
ACTRN12613000590763. The STAndards for Reporting of Diagnostic accuracy (STARD) 
checklist was consulted to ascertain optimal study reporting. 
Participants were recruited 1) from the QSkin Study 18 a population-based cohort study in 
Queensland (43,794 people enrolled); and 2) through a call for community volunteers. We 
mailed invitations to 500 QSkin participants residing within the greater Brisbane area, age 50-64 
years, at high risk of melanoma (fair skin type, previous skin excisions, personal or family 
history). An additional 59 participants approached us requesting participation after learning 
about the study via University websites or in the local news (see Figure 1 - patient flow).  
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Once eligibility was confirmed, participants completed a questionnaire on teledermatology 
acceptance (data not reported here), if they had access to an iPhone, and whether they would be 
interested in participating in a study of SSE plus mobile teledermoscopy.  
The target sample size for this pilot trial was 50; we estimated a drop-out rate of 15% based on 
our previous studies. Among all participants who completed the questionnaire (n=230), the first 
58 who expressed interest and had a suitable smartphone were enrolled and mailed the 
Handyscope Fotofinder dermoscope attachment.19 They were asked to take photos of moles or 
spots they “did not like the look of”. They were not given a defined number of lesions they 
should submit. They received instructions about how to select for photographing a lesion using 
the ‘asymmetry and colour’ (AC) rule 20 and were provided with technical instructions on how to 
download the Handyscope App, use the dermoscope to obtain and send magnified images, and 
take a second clinical image to verify the anatomical site of each skin lesion. Participants were 
randomised (via a computer-generated random number list) to either SSE instructions 
intervention or no SSE instructions control groups. Allocation was completed by the research 
assistant and concealed from participants and all other study personnel. In addition to the above 
instructions (AC rule and technical instructions), the intervention group received detailed and 
specific  instructions on how to conduct a thorough SSE (10-step guide used in our previous 
trials17), which we expected to increase the number of body areas people looked at and decrease 
the number of lesions missed.  
Participants completed the SSE within three weeks. The teledermatologist (HPS) (board certified 
with experience in teledermoscopy), was blinded to intervention or control group allocation.  For 
each submitted lesion he indicated whether the photograph was suitable to provide a diagnosis.  
If so, he suggested a primary diagnosis, with up to two differential diagnoses and whether CSE 
was required. All participants received a CSE independent of this advice. 
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Of the 58 enrolled participants, 50 attended a CSE within three months of SSE at the Queensland 
University of Technology. The CSE was performed by a dermatology registrar (MM) under 
supervision of the same dermatologist who undertook telediagnosis (See Figure 1 for reasons 
why eight people discontinued participation and Table 1 for patient characteristics). Of these, 
seven left the study soon after providing consent but before providing any data. Two participants 
provided teledermoscopy images, but were lost to follow up. The data of these two latter 
participants was excluded. Based on the telediagnoses, significant alterations of skin lesion 
diagnoses were not expected within the study time frame. During CSE, clinicians noted any 
lesions that required further management, photographed them and sent the images and a letter to 
the participant’s usual family doctor.  Internationally there are differences in the nomenclature 
surrounding naevi.21 For this report, we grouped naevi into benign naevi and atypical naevi, 
which are lesions clinically suspicious of malignancy. Participants were reimbursed with a 
$100(AU) voucher to cover costs and time. One participant was excluded at the clinic visit due 
to being outside the age limit, 49 participants remained for analyses (25 intervention; 24 control 
group). 
Statistical analysis:  
Analyses were conducted with IBM SPSS version 21.0. Intention to treat analysis was used 
keeping all data from the participants within their assigned SSE instruction groups. We 
summarised participants’ characteristics, number and type of lesions sent via mobile 
teledermoscopy, found at CSE, or missed (considered worthwhile photographing or further 
clinical monitoring at CSE), using descriptive statistics, and compared the proportions of lesions 
submitted for telediagnosis and missed within the SSE instructions and no instruction groups 
using Chi-Square test. We calculated sensitivity and specificity by utilising 2x2 tables cross 
referencing the tele- and CSE-diagnoses. A skin lesion was counted as positive if it required 
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further intervention including close monitoring, biopsy, excision or other treatment, and negative 
if it did not require such interventions.   
We calculated sensitivity and specificity in two of ways:  
Participant-level analysis: assigned the participant a positive score if at least one lesion identified 
during SSE+ mobile teledermoscopy or CSE required the participant to see a doctor for follow-up 
(sensitivity formula = number of participants who identified at least one suspicious lesion during 
SSE + mobile teledermoscopy and confirmed during CSE, divided by  number of patients with 
positive lesion identified during SSE or CSE; specificity formula = number of patients without at 
least  one lesion requiring treatment or follow up which were also identified as such by SSE plus 
mobile teledermoscopy  or CSE ).Thus a participant who overlooked a lesion during SSE but also 
correctly identified one that required a CSE was considered a true positive (this method assumes 
the doctor will pick up the overlooked lesion during the follow-up consultation).  
Lesion-level analysis: using the lesion as the denominator (sensitivity formula = number of 
lesions submitted by participants and also found suspicious on CSE, divided by the number of 
positive lesions identified during SSE or CSE; specificity formula = number of lesions not requiring 
treatment or follow up identified at SSE plus mobile teledermoscopy which were also identified as 
such by SSE plus mobile teledermoscopy  or CSE). These analyses were adjusted for clustering of 
lesions within patients: we applied both the ratio estimator and variance inflation factor 
methods described by Genders TS et al.22, using an appropriately modified excel spreadsheet 
provided by the above authors to obtain adjusted confidence intervals. As both resulted in 
almost identical confidence intervals, only the ratio estimator results are reported. 
Kappa statistics determined agreement (corrected for chance) between tele- and CSE-diagnoses 
with and without accounting for differential diagnoses.  
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Results  
The age of the 49 participants ranged from 50-64 years; 49% were male and 49% had a history 
of at least one skin cancer in the past. Overall, 31% had a known first degree family member 
with melanoma and 90% self-reported a fair skin type (Table 1).   
SSE+ mobile teledermoscopy 
Participants performed SSE plus mobile teledermoscopy in their homes and attended CSE 
between May and November 2013. Overall, 309 lesion images (median five per person in both 
control and intervention groups, range 0-21) were submitted. Of these, two were of poor quality 
and did not allow telediagnosis; three showed only the anatomical location but excluded the 
dermoscopic image. To be conservative, we assumed that these five lesions (1.6%) required CSE 
in the analysis. The most common lesions submitted by both groups were benign naevi (n=153), 
seborrhoeic keratoses (n=86), and actinic keratoses (n=29)). Overall, seven submitted atypical 
naevi images were suspicious for melanoma, six for basal cell carcinomas (BCC) and one for 
squamous cell carcinoma (SCC).  
Based on images, the teledermatologist determined that 34 (68%) participants had at least one 
lesion that required clinical follow-up or treatment (15 intervention group, 19 control group, 
p=0.22) (Table 2).  
Participants submitted lesion images from the body sites listed in Table 2. The intervention 
group was more likely to submit images of leg lesions, whereas the control group was more 
likely to submit images of arm lesions (p=0.03). There were no other significant differences 
between the groups with regards to body site, number of lesions missed or lesion types. 
Clinical Skin Examination  
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At the CSE, the dermatologist identified an additional 40 lesions on 25 people (intervention 
group: 22 lesions on 13 people; control group: 18 lesions on 12 people) (Tables 2 and 3).  Most 
of the lesions missed (n=24) did not meet the AC rule criteria, and, therefore, were lesions not of 
primary concern for melanoma. There was no statistically significant difference between the 
intervention and control groups in number of missed lesions (p=0.57). Men were somewhat more 
likely than women to miss a lesion (64% vs 36%, respectively; p=0.09).  
Overall, 11 participants (22%) missed 14 pigmented lesions which, according to the 
dermatologist, required close monitoring/biopsy or met AC rule criteria (Table 3).  Intervention 
or control group, gender, a personal or family history of melanoma were not significantly 
associated with missing these lesions.  
As there were only minimal differences between the intervention and control group outcomes we 
pooled the data for subsequent analyses.  
Sensitivity and Specificity 
At the participant level analysis, SSE plus mobile teledermoscopy had a sensitivity of 81.8% 
(95% CI 64.5-93.0) and a specificity of 56.3% (95% CI 29.9-80.2) (Table 4). The six participants 
causing a reduction in sensitivity missed the following lesions: two benign naevi which required 
monitoring, a growing benign naevus that could occlude a nare, an atypical seborrhoeic keratosis 
for monitoring, and three lesions with BCC as possible differential diagnoses. At the lesion level 
analysis SSE plus mobile teledermoscopy had a sensitivity of 41.9% (95% CI 27.6-56.2) and 
specificity of 89.6% (95% CI 83.9-95.2). 
The sensitivity and specificity of teledermatology compared to CSE based only on the lesions 
submitted by participants via mobile teledermoscopy (but excluding lesions later found on CSE), 
was 91.2% (CI 81.6-100) and 89.6% (CI 85.9-93.2), respectively.  The overall diagnostic 
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concordance between the tele- and clinical diagnosis was 89.8% (Kappa = 0.74; SE 0.04), 
indicating substantial agreement, Kappa further improved further to 0.90, SE 0.02, when up to 
two differential diagnoses were included. 
Discussion 
Irrespective of SSE instructions received, both groups submitted and missed a similar number of 
lesions. The intervention group was more likely to submit images from the legs compared to the 
control group, but this did not improve their ability to find all lesions which were concerning on 
CSE. Previous teledermatology and teledermoscopy studies mostly used a clinic-based design 
whereby participants were photographed by a researcher just before seeing the dermatologist. In 
contrast, our study is novel because it places dermoscopy in the hands of the consumers.  Our 
null results could either indicate that the 10-step guide is insufficient to improve thoroughness of 
SSE, or that the mobile teledermoscopy instructions sufficiently guided people towards a 
thorough SSE in both groups. The latter seems more likely because both groups submitted more 
than 30% of lesions from the back, which is important as the back is a common location of 
melanoma in both men and women.23 Mobile teledermoscopy would need to be a partner assisted 
technology to photograph hard to see body areas. Our study was however small and may have 
been underpowered to detect more subtle differences in lesion detection patterns. 
Both groups overlooked a similar number of lesions, and we combined them for clinical 
accuracy analyses. Previous reports of SSE accuracy vary widely, with sensitivities ranging from 
25-93% and specificities ranging from 83-97%.8 These estimates were often derived by 
comparing patient versus doctor mole counts, or asking participants to identify changes of lesion 
images which were digitally altered.24 Very few studies attempted to assess SSE performance in 
a more natural setting, likely owing to the absence of reliable methods for such an assessment. 
Dermoscopy has been shown to improve consumers’ ability to diagnose melanoma25 in 
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particular when instructed on the AC rule.26  However it was apparent in our study findings, 
(corroborating our previous findings),27 that consumers tend to photograph many non-concerning 
lesions such as actinic or seborrhoeic keratoses indicating that better training or instructions are 
needed to improve lesion selection. On the other hand, even the very well trained general 
practitioners in Australia need to excise about 20 benign lesions for every melanoma,28 
indicating that some selection of benign lesions in an early detection context will be unavoidable.     
SSE plus mobile teledermoscopy showed a high sensitivity in the participant level analysis 
(81.8%), with a marked reduction in lesion level analysis (41.9%). The participant level analysis 
assumed that if a patient attends with one submitted worrying lesion, the doctor will complete a 
whole-body CSE and identify the other lesion of concern, which may not always be the case. 
The segmental analysis becomes relevant as some patients may request only a specific lesion be 
checked, potentially overlooking a melanoma on another site. Indeed, a pharmacy group in 
Australia has announced a new health program called ‘spot check’, 29 wherein family doctors 
provide a teledermoscopy diagnosis for one to three concerning lesions photographed at 
pharmacies. Patients who receive reassurance about submitted lesions may then not attend a 
doctor for a CSE.   
The importance of a whole-body CSE is reinforced by several studies which indicate that up to 
one third of melanomas may be missed if only the index lesion is examined.30-32. Despite the 
participants overlooking some pigmented lesions, the gravity of this should be considered in the 
light of waiting times for dermatological review currentlyapproximately 38 days (range 20-73) 
for a patient with a changing mole in the USA, .33 In public hospitals in Queensland, Australia, 
only 47-55% of urgent patients are seen within 30 days.34,35 Perhaps SSE plus mobile 
teledermoscopy could be utilised as a triage tool, expediting urgent patients . The high rate of 
agreement between the teledermatologist and clinical examination lesion diagnosis is consistent 
with other studies of well-trained teledermatologists12,13, but needs to be confirmed for doctors 
14 
 
 
with little or no dermatology training. The lower sensitivity of 41.9% in the segmental analysis 
was also affected by the large number of non-pigmented lesions, particularly actinic keratoses 
and BCCs that were missed, but later deemed worthy of investigation during the CSE.  These 
lesions were included in the analysis, because rare but serious tumours such as amelanotic 
melanomas may also not meet the AC rule. Better education or the use of or a modified version 
of the AC rule, or replacement of the AC rule completely with a dermoscopy checklist may 
improve its sensitivity to acceptable levels.36 
Clinical application  
Our results indicate that the most relevant clinical application for mobile teledermoscopy would 
be as a triage tool for consumers concerned about a particular lesion.  This is very relevant for 
(1) consumers who have had a prior melanoma and are at greater risk of developing a second 
melanoma37 or (2) consumers asked  to monitor a particular mole. The high agreement rate 
between image and clinical opinion at least in the hands of an experienced teledermatologist is 
reassuring for this application. The high sensitivity from the participant level analysis is 
encouraging; however it relies on practitioners performing or patients demanding a CSE of the 
whole body at the subsequent in-person visit, and a health professional, who is competent in, and 
willing to perform a whole body CSE.  
Limitations  
The small sample size may have reduced the power to detect significant differences between the 
intervention and control groups. Both the telediagnosis and clinical diagnosis were performed by 
only one dermatologist (plus a trainee), which could have artificially increased the estimates of 
accuracy of the telediagnosis, despite the dermatologists being blinded to the participants’ 
allocated group. In the Lamel et al study, the diagnostic concordance between two 
dermatologists for clinical examination diagnoses was 91.7% and for teledermatology 100%.12 
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Comparing  the telediagnosis of 11 dermatologists differing in their years of practice to 
histopathology , an average of 85% (77% to 95%) of the telediagnoses were correct, with the 
level of accuracy differing by teledermatologists’ experience.38 More recently Borve et al 
assessed whether teledermoscopy referrals from primary care physicians reduced the waiting 
time for surgical treatment in which four dermatologists were involved assessing the 
telereferrals. The study reported that of 346 lesions referred via teledermoscopy as benign 
without differential diagnosis, 99.1% were also clinically diagnosed as benign. However, the 
decisions of the four dermatologists were not compared.39 We did not conduct a full mole count 
on each participant and specificity calculations are therefore based on those lesions that the 
participants submitted for mobile teledermoscopy review and that the dermatologist found not 
requiring any further treatment only. This will have decreased specificity estimates considerably 
from what we may expect if most participants had ten moles or more.  
We used face-to-face diagnosis as the reference standard over histopathology.  Histopathology is 
not practical when lesions are considered benign or when clinical diagnoses prompt immediate 
treatment, such as cryotherapy of actinic keratosis. While all potential applications of mobile 
teledermoscopy rely on having an experienced clinician, a previous study has displayed high 
concordance (Kappa = 0.84) when comparing telediagnoses to histopathology.40  
Conclusions 
We found no evidence that providing participants with mobile teledermoscopy in addition to detailed 
SSE instructions significantly increased the body sites examined (except the legs) or decreased 
number of lesions missed. Both groups submitted many benign lesions and further improved 
instructions are needed. Good quality dermoscopic images can be taken by consumers in their home 
environment using their smartphones with a dermoscopy attachment, and enable diagnoses to be made 
confidently by the teledermatologist. The telediagnosis shows very high agreement, sensitivity and 
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specificity compared to CSE. Enhanced SSE shows great potential for triage and/or surveillance of 
lesions. However, further improvements in the consumer instructions are required to reduce the 
number of missed lesions. The AC rule only applies to pigmented lesions and may not adequately 
instruct people on which non-pigmented lesions should be selected.   
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Table 1: Participant characteristics and primary teledermatology diagnoses of submitted lesions 
Characteristic Control 
n (%) 
Intervention 
n (%) 
Total 
n (%) 
Gender n=49 (%)    
     Male  11 (46) 13 (52) 24 (49) 
     Female 13 (54) 12 (48) 25 (51) 
Age n=49 (%)    
     50-54 8 (33) 11 (44) 19 (39) 
     55-59 11 (46) 5 (20) 16 (32) 
     60-64 5 (21) 9 (36) 14 (29) 
Educational Attainment* n=49 (%)    
     School or intermediate certificate 1 (4) 3 (12) 4 (8) 
     High School or leaving certificate 2 (8) 3 (12) 5 (10) 
     Trade/ apprenticeship 1 (4) 2 (8) 3 (6) 
     Certificate/ diploma 5 (21) 5 (20) 10 (20) 
     University degree 15 (63) 11 (44) 26 (53) 
Work n=49 (%)    
     Full-time (including self-employed)  20 (83) 18 (72) 38 (78) 
     Part-time  1 (4) 2 (8) 3 (6) 
     Home duties - 2 (8) 2 (4) 
     Retired/ Student 3 (13) 3 (12) 6 (12) 
How many skin cancers have you ever had cut off your 
skin? n=49 (%) 
   
     20 + skin cancers 1 (4) 2 (8) 3 (6) 
     10-20 skin cancers 2 (8) - 2 (4) 
     2-10 skin cancers 4 (17) 5 (20) 9 (18) 
     1 skin cancer 3 (13) 7 (28) 10 (20) 
     none 14 (58) 11 (44) 25 (51) 
First degree relative history of melanoma) n=49 (%)     
     Yes 7 (29) 8 (32) 15 (31) 
     No 14 (58) 13 (52) 27 (55) 
     Don’t know 3 (13) 4 (16) 7 (14) 
Natural skin colour  n=49 (%)    
     Fair 22 (92) 22 (88) 44 (90) 
     Medium 1 (4) 3 (12) 4 (8) 
     Olive/Dark 1 (4) - 1 (2) 
Primary Teledermoscopy Diagnoses  n=153 n=156 n=309 
Predominantly pigmented lesions  
Atypical naevus 
Benign naevus  
Solar lentigo 
Seborrhoeic keratosis 
 
6 
77 
12 
34 
 
1 
76 
2 
52 
 
7 
153 
14 
86 
Non pigmented lesions 
BCC 
SCC/IEC 
Actinic keratosis 
Angioma 
Telangiectatic mat 
Excoriated prurigo nodule 
Non-specific erythema 
 
1 
1 
16 
1 
1 
0 
1 
 
5 
0 
13 
4 
0 
1 
0 
 
6 
1 
29 
5 
1 
1 
1 
Other 
No dermoscopic image sent 
Unable to be assessed 
 
3 
0 
 
0 
2 
 
3 
2 
21 
 
  
 
BCC: basal cell carcinoma, SCC: squamous cell carcinoma, IEC:  intra-epidermal carcinoma  
*1 participant missing Educational Attainment 
  
Table 2: Per person and per lesion outcomes of control and intervention groups 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Control n=24 (%) Intervention n=25 (%) Totals p-values 
SSE plus mobile teledermoscopy:     
Had help from a partner for SSE n (%) 19 (79.0%) 23 (92.0%) 43 (86.0%) p=0.22 
Number of lesions submitted;  median (range) 5  (0-15) 5  (1-21) 5 (0-21)  
Site of lesions n (%) 
Head & neck 
Chest & abdomen 
Back 
Arms 
Legs 
 
 
19 (12.4%) 
28 (18.3%) 
55 (35.9%) 
31 (20.3%) 
20 (13.1%) 
 
 
25 (16.0%) 
29 (18.6%) 
51 (32.7%) 
15 (9.6%) 
36 (23.1%) 
 
 
44 (14.2%) 
57 (18.4%) 
106 (34.3%) 
46 (14.9%) 
56 (18.1%) 
 
p=0.03 
Participants needing a in-person review  
based on telederm diagnosis 
19 (76%) 15 (60%) 34 (68%) p=0.22 
Clinical Skin Examination     
Sites missed of lesions n (%)  
Head & neck 
Chest & abdomen 
Back 
Arms 
Legs 
Total n lesions 
 
6 (33.3%) 
2 (11.1%) 
2 (11.1%) 
3 (16.6%) 
5 (27.7%) 
18 
 
6 (25.0%) 
3 (12.5%) 
3 (12.5%) 
4 (16.7%) 
6 (25.0%) 
24 
 
12 (30.0%) 
5 (12.5%) 
5 (12.5%) 
8 (20.0%) 
12 (30.0%) 
401 
p=0.99 
N of participants who missed a pigmented lesion  5 (20.0%) 6 (24.0%) 11 (22.0%) p=0.73 
N of pigmented lesions missed  4 (28.0%) 10 (71.0%) 14 (100%) p=0.12 
SSE: skin self-examination     
  
Table 3: Clinical diagnosis for a) lesions submitted during SSE, and b) lesions found during CSE but missed during SSE  
 Control group Intervention group Dermatologist’s treatment recommendations 
 a) Found on 
SSE 
b) Missed on 
SSE 
a)Found on 
SSE 
b) Missed on SSE  
Predominantly pigmented      
Atypical naevus 0 2 1 1 Biopsy/Excision (4) 
Benign naevus  79 (46) 2 (2) 77 (23) 7 (5) Excision (2, including 1 intradermal naevus, which could occlude the nare), 
close review (11) 
Solar lentigo 17 0 5 0 Biopsy (1) 
Seborrhoeic keratosis 32 2 47 0 Atypical/irritated – close monitoring (1), biopsy (1) 
Sub total (pigmented) 128 6 130 8  
Non pigmented      
BCC 1 2 4 6 Biopsy (3),curette and curettage, cryotherapy if superficial(5), excision(5 
SCC/IEC 0 1 0 0 Biopsy(1) 
Actinic keratosis 13 8 8 5 Biopsy(1)/Monitor(1)Cryotherapy/Field treatment eg 5-Fluorouracil (32) 
Atypical dermatofibroma 0 0 0 2 Excision or monitoring (2) 
Other 7 1 9 1 Differential Diagnosis BCC (3) Close review  
Sub total (non pigmented) 21 12 21 14  
Removed prior to 
examination 
No lesion found now 
3 
 
1 
- 
 
- 
1 
 
4 
 
- 
 
- 
2 removed at our request prior to examination (BCC with a differential of 
amelanotic melanoma(1), atypical naevus(1)), Others managed by general 
practitioner seborrhoeic keratosis (1), solar lentigo(1) 
Totals 153 18 156 22  
SSE: skin self-examination,  CSE: clinical skin examination, BCC: basal cell carcinoma, SCC: squamous cell carcinoma, IEC:  intra-epidermal carcinoma  
16 lesions were excluded from missed lesion analysis. Although these were not submitted for telediagnosis, the participant asked about them prior or during the clinical examination. In addition, 2 
lesions which had been missed by the participant, but were treated by a doctor prior to CSE were also excluded. 
  
Table 4: Clinical accuracy of SSE + mobile teledermoscopy compared to CSE 
 CSE (positive) Yes  No Yes No Concordance  Sensitivity  95% CI Specificity   95% CI PPV NPV 
 SSE + mobile 
teledermoscopy 
(positive) 
Yes 
(a) 
Yes 
(b) 
No 
(c) 
No 
(d) 
 
(a+d)/ 
(a+b+c+d) 
 
a/(a+c) 
  
d/(b+d) 
   
(a/a+b) 
 
(d/c +d) 
 
Participant level analysis.1 
(n=49) 
 
 
27 
 
7 
 
6 
 
9 
 
73.5% 
 
81.8% 
 
64.5-93.0 
 
56.3% 
 
29.9-80.2 
 
79.4% 
 
60.0% 
Overall lesion level  
analysis 2,3,4 (n=341) 
32 28 43 238 79.4% 41.9% 27.6-56.2 
 
89.6% 83.9-95.2 
 
53.3% 84.9% 
Teledermatology analysis  
of lesions submitted via SSE + 
mobile teledermoscopy 
(n=301) 
Cluster adjustment: 
     Ratio estimator 
     Variance inflation        
     factor 
 
32 28 3 238 89.8% 91.2% 81.6-100 
 
 
 
81.4-101 
81.6-100 
 
89.6% 85.9-93.2 
 
 
 
83.9-95.2 
84.0-95.1 
53.3% 96.4% 
SSE: skin self-examination, CSE: clinical skin examination,  
1 positive finding = at least one lesion identified during SSE + mobile teledermoscopy or CSE required the patient to see a doctor for follow-up or treatment. 
2 positive finding = any lesion which required the patient to see a doctor for follow up or treatment 
3 Excluded from analysis: 8 lesions that were either removed prior to face to examination or could not be found at face to face examination  
4, confidence interval adjusted for clustering of lesions, using Ratio estimator 
 
 
 
